Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$8.40 USD
+0.26 (3.19%)
Updated May 31, 2024 04:00 PM ET
After-Market: $8.38 -0.02 (-0.24%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.40 USD
+0.26 (3.19%)
Updated May 31, 2024 04:00 PM ET
After-Market: $8.38 -0.02 (-0.24%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Zacks News
Should You Buy Voyager Therapeutics (VYGR) Ahead of Earnings?
by Zacks Equity Research
Voyager Therapeutics (VYGR) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Abbvie's Uterine Fibrosis Candidate Meets Goal in Study
by Zacks Equity Research
AbbVie's (ABBV) phase III study of its late stage candidate elagolix meets its primary endpoint in women with uterine fibroids.
Ophthotech Begins Phase II Zimura Study in Stargardt Disease
by Zacks Equity Research
Ophthotech (OPHT) is focusing on Zimura following the failure of the Fovista studies.
Voyager Therapeutics (VYGR) Jumps: Stock Rises 7.8%
by Zacks Equity Research
Voyager Therapeutics (VYGR) was a big mover last session, as the company saw its shares nearly 8% on the day amid huge volumes.
Voyager Therapeutics (VYGR) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Voyager Therapeutics, Inc. (VYGR) has been struggling lately, but the selling pressure may be coming to an end soon